Veracyte Inc
NASDAQ:VCYT
Operating Margin
Veracyte Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Veracyte Inc
NASDAQ:VCYT
|
2.3B USD |
4%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
344.2B USD |
29%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
154.2B USD |
22%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
130.2B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
129.6B USD |
40%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
121.6B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
65B USD |
30%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
34.6B EUR |
-1%
|
Veracyte Inc
Glance View
Veracyte Inc., founded in 2008, operates at the intriguing intersection of biotechnology and diagnostics, leveraging genomic insights to transform the landscape of disease diagnosis. The company's core mission is to improve the accuracy and efficiency of diagnostic testing, thus enabling better treatment decisions. Veracyte has woven innovation into its business model, creating a suite of genomic tests primarily for oncology and pulmonology. These tests are designed to resolve diagnostic ambiguity, particularly in cases where traditional tests might fall short. By harnessing advanced genomic technology, Veracyte empowers healthcare providers with definitive answers, thus facilitating timely and appropriate patient management. The company's revenue engine is driven by its extensive portfolio of products and services. At the heart of its operations is a series of diagnostic tests—such as Afirma for thyroid cancer, Percepta for lung cancer, and Envisia for idiopathic pulmonary fibrosis—each of which addresses key unmet medical needs. Veracyte generates income by selling these tests primarily to hospitals and healthcare providers, who in turn utilize the insights to bolster their clinical decision-making. Additionally, the company licenses its proprietary biobank and genomic platform to partners in research and pharma industries, unlocking further monetary streams. As payers increasingly recognize and reimburse the value of these precision diagnostic tools, Veracyte continues to strategically expand its market reach, reinforcing its role as a vital player in the biotech domain.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Veracyte Inc's most recent financial statements, the company has Operating Margin of 4.4%.
You don't have any saved screeners yet